Your browser doesn't support javascript.
loading
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.
Gandhi, Shiv; Klein, Jonathan; Robertson, Alexander J; Peña-Hernández, Mario A; Lin, Michelle J; Roychoudhury, Pavitra; Lu, Peiwen; Fournier, John; Ferguson, David; Mohamed Bakhash, Shah A K; Catherine Muenker, M; Srivathsan, Ariktha; Wunder, Elsio A; Kerantzas, Nicholas; Wang, Wenshuai; Lindenbach, Brett; Pyle, Anna; Wilen, Craig B; Ogbuagu, Onyema; Greninger, Alexander L; Iwasaki, Akiko; Schulz, Wade L; Ko, Albert I.
Afiliación
  • Gandhi S; Section of Infectious Diseases, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA. shiv.gandhi@yale.edu.
  • Klein J; Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
  • Robertson AJ; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
  • Peña-Hernández MA; Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
  • Lin MJ; Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA, USA.
  • Roychoudhury P; Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA, USA.
  • Lu P; Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
  • Fournier J; Section of Infectious Diseases, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.
  • Ferguson D; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA.
  • Mohamed Bakhash SAK; Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA, USA.
  • Catherine Muenker M; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
  • Srivathsan A; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
  • Wunder EA; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
  • Kerantzas N; Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Wang W; Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.
  • Lindenbach B; Department of Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, USA.
  • Pyle A; Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.
  • Wilen CB; Department of Chemistry, Yale University, New Haven, CT, USA.
  • Ogbuagu O; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
  • Greninger AL; Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
  • Iwasaki A; Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Schulz WL; Section of Infectious Diseases, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.
  • Ko AI; Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Nat Commun ; 13(1): 1547, 2022 03 17.
Article en En | MEDLINE | ID: mdl-35301314

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tratamiento Farmacológico de COVID-19 Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tratamiento Farmacológico de COVID-19 Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido